Evolus (EOLS) Leerink’s Global Healthcare Conference 2025 summary

Business model and market positioning

• Emphasizes a performance beauty, cash-pay strategy targeting millennials and supporting small practices.

• Achieved 14% market share in toxins, with 30% growth in Q4 despite broader market slowdown.

• Subscription program, Club Evolus, offers wrinkle-free treatment for $49/month, increasing patient frequency and lifetime value.

• Focus on reinvestment in clinics and evolving branding as the millennial demographic ages.

• Differentiates from larger pharma competitors by acting as a business partner to clinics.

Product innovation and launches

• Launched Evolysse, a new injectable hyaluronic acid filler, with a unique label mentioning weight loss as a use case.

• Evolysse demonstrated statistical superiority to Restylane in clinical trials and is the first to claim efficacy for weight loss-related volume loss.

• Launch strategy includes extensive training, sampling, and a phased rollout, with revenue expected to ramp in Q4.

• Plans to expand the filler line internationally, starting with the Estyme line in Europe in the back half of the year.

• Pipeline includes new Evolysse products and innovation in biostimulatory and skin quality injectables.

Market trends and growth dynamics

• Toxin market remains resilient, growing mid-to-high single digits even during economic downturns.

• Filler market is more volatile, with highs and lows, but expected to rebound and benefit from GLP-1 weight loss trends.

• GLP-1 users are a key growth segment for fillers, as weight loss patients seek volume restoration.

• U.S. and international markets are healthy, with med spas and clinics expanding and hiring.

• Long-term market growth is projected at around 10% annually, with younger generations driving adoption.